ETC Blog

What do ocean-going yachts, space-traveling bacteria and synthetic life have in common? J. Craig Venter, of course. The self-styled genome tycoon has been busy pushing the boundaries on what may appear at first glance to be unrelated enterprises. Nothing could be further from the truth. A suite of recently uncovered patent applications lodged by Venter and his colleagues reveal not only an attempt to grab ownership over much of synthetic biology (see news release) but also a breathtakingly bold business plan for producing millions of new synthetic organisms per day. At the heart of this are plans for a new, automated process enabling rapid assembly of complete synthetic genomes - plans that, if realised, could render current genetic engineering techniques quaint and obsolete. Venter calls it “homologous in vitro recombination” or “combinatorial genomics.” ETC suggests it might be properly dubbed “shotgun synthesis” and it has the potential to blast apart current biotech practice.

Read the rest of this entry

Some of us from ETC are in Zurich for the next few days observing what happens when you cram several hundred synthetic biologists and industrialists into a conference room — the evolution of a new industrial species? These ‘Synthusiasts’ are now into their third annual international congress, Synthetic Biology 3.0, each conference named like a […]

Read the rest of this entry

As well as dealing with Monsanto in Munich this week, ETC Group has also been raising the alarm about a massive geo-engineering experiment scheduled for this month around Galapagos by Planktos Inc. Here is an open reply to a public attack on our press release.

Read the rest of this entry

On October 10, ETC Group attended the US Food and Drug Administration’s first public meeting on nanotechnology. About 40 people had signed up to make presentations, and we were each given eight minutes to say our piece to the FDA’s newly-formed Nanotechnology Task Force. (You can read the text of ETC Group’s presentation here.)

It […]

Read the rest of this entry

Nano-Drug’s Dirty Little Secret

ETC Group’s September 2006 report on nanomedicine, Nanotech Rx, requires some updating. After all, it’s nearly 30 days old. Our report mentions the nano-drug Abraxane, and it acknowledges that approval of the cancer drug was a watershed event for the nanotech industry. But important details are emerging. On October 1 the […]

Read the rest of this entry

The Economist this week has a Special Report on Synthetic Biology , the new field of building artificial life forms from scratch. As is to be expected from the Economist, this is a fairly upbeat assesment of the technology that fails to mention the growing opposition to Synthetic Biology, signalled a few months ago when almost forty civil society groups, trade unions and scientific associations signed an open letter calling for caution.

Here at ETC we have been busy writing our own special report on Synthetic Biology (which we are calling ‘Extreme Genetic Engineering’ - watch this space!). You can expect it to be a bit more critical than the Economist.

Read the rest of this entry

While some ETC Group staff were in Caracas strategizing with partners to strengthen the global opposition to Terminator, others of us were subjected to the slog of the CBD meeting in Granada. And one of us was spending a few days with unlimited access to free chocolate at Swiss Re’s opulent Centre for Global Dialogue near Zurich. Swiss Re, the world’s largest re-insurer (an insurer of insurance companies) is concerned - no surprise - about those risks associated with nanotechnology that may result in financial losses for the company.

Read the rest of this entry

Not content with heading for the stars, the corporate sponsored X-Foundation that awards the X-prize has now set a bounty for commericalising the neXt frontier - the human genome. According to this article in the Wall Street Journal the X-foundation will award a new X-prize of between $5-$20 million to the first inventor of a gene sequencer that can decode the DNA of 100 people in a matter of weeks. behind it is craig venter, the genomics mogul.

Read the rest of this entry

Some of us at ETC have just spent the past three days in a drafting group for the Dag Hammarskjold Foundation’s inspiring What Next? project. Hopefully we will write more about What Next? as it gets closer to completion. Briefly the What Next? project its an attempt to stop, reflect and look forward to the […]

Read the rest of this entry

Welcome to our ETC Blog - an occassional space for analysis, links and flagging up some of the more interesting stuff that ETC staff are reading, writing and thinking about on a day to day basis.

Read the rest of this entry